Why 3 secretive biotechs are keeping their science close to the chest

Startups like Altos Labs are keeping pipeline details scarce to protect their ideas from competitors — but some experts say stealth only works for biotechs with deep pockets.

By Kelly Bilodeau • July 27, 2026

Lilly’s leap into psychedelics; peptides in the spotlight

Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs. 

By PharmaVoice Staff • July 24, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

Biopharma challenges leaders want to tackle

Boosting public trust, delivering genuine breakthroughs and getting trials off the ground remain top-of-mind issues in the industry.

By Meagan Parrish • July 23, 2026

As the Ebola outbreak rages, new treatments are headed into trials. Will they work?

The strain causing the current outbreak has no approved treatments or vaccines but global organizations are rushing to change that.

By Alexandra Pecci • July 20, 2026

Long days, dinners with copious alcohol, and the hunt for emerging assets in China

Why building relationships, navigating cultural nuances and preparing for different deal structures are key to investing in China’s promising drugs.

By Meagan Parrish • July 17, 2026

This startup thinks humans in clinical trials could become a ‘formality’

Deep Origin is attempting to create “virtual humans” that could one day reduce late-stage safety failures and the need for animal testing.

By Alexandra Pecci • July 16, 2026

Galimedix is keeping the amyloid hypothesis alive

The right target but the wrong approach? Why Galimedix’s co-founder believes the company has found an edge in treating Alzheimer’s disease with an amyloid drug.

By Kelly Bilodeau • July 14, 2026

Biotech funding gap widens despite rebound in VC investment

Nearly 70 venture-backed biotech startups raised more than $9.1 billion between January and June, but the majority already had drugs in testing.

By Gwendolyn Wu • July 14, 2026

HHS plan to speed drug R&D won’t remove ‘self-inflicted’ delays

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

By Kelly Bilodeau • July 8, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

Doctor-turned-dealmaker reveals his M&A playbook

Dr. David Hung is pulling multiple financial levers to put Nuvation Bio on strong footing as it advances its oncology drugs.

By Kelly Bilodeau • July 1, 2026

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.

By Kelly Bilodeau • June 30, 2026

3 late-stage MASH drugs that could rival Rezdiffra

The red-hot market has plenty of room for additional therapies from big name players and clinical stage companies alike.

By Alexandra Pecci • June 29, 2026

BIO 2026: Where pharma leaders say AI hasn’t delivered

AI hasn’t always been what it was cracked up to be in pharma. Here’s where execs say the technology hasn’t lived up to the hype.

By Meagan Parrish • June 26, 2026

‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in offerings later this year — but only among companies fitting a certain criteria.  

By Gwendolyn Wu • June 23, 2026

Backed by Sanofi and Roche, Orano Med chases radiopharma leadership

Orano Med’s industrial platform offers “unlimited” and unique access to the cancer-fighting alpha emitter lead-212.

By Alexandra Pecci • June 22, 2026

As M&A rebounds, here’s how pharmas can prepare to seal a deal

Drugmakers that aren’t ready when financial opportunity knocks could get caught flat-footed in a competitive market.

By Kelly Bilodeau • June 18, 2026

A new Westlake-backed biotech takes aim at migraines

Vedana Therapeutics recently emerged from stealth with $46 million to support its mission of developing “anti-PACAP” therapies, an increasingly popular strategy for migraine prevention.

By Jacob Bell • June 18, 2026

Corvus CEO thinks his next blockbuster is an ITK inhibitor

It’s like “Rituxan all over again,” said CEO Richard Miller, who believes Corvus’ lead candidate could make an impact in both cancer and autoimmune diseases.

By Alexandra Pecci • June 16, 2026

The biotech market is rebounding. So where are the executive jobs?

The industry is showing favorable economic signs, but biotech companies are still taking a measured approach to hiring leaders.

By Kelly Bilodeau • June 15, 2026

Competition is brewing between ADCs and bispecifics

The dueling modalities are each gaining traction in lung cancer. But will they ultimately become allies?

By Kelly Bilodeau • June 11, 2026

Amid a flurry of biotech deals, China looks to keep innovation at home

The country's new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing game for foreign companies.

By Kelly Bilodeau • June 10, 2026

With a promising MASH asset, muscle-sparing GLP-1 and new CEO, Rivus gets ready to make its mark

Rivus Pharmaceuticals’ CEO Jorge Bartolome said the biotech is on track to build a “truly differentiated” cardiometabolic portfolio.

By Alexandra Pecci • June 9, 2026

3 potential takeover targets in obesity

Momentum is building to bring a next-generation weight loss drug to market, which could set up these three biotechs to strike a deal with a larger pharma.

By Kelly Bilodeau • June 8, 2026

BMS under pressure in schizophrenia; Summit/Akeso on a winning streak

While the large pharma’s new drug Cobenfy has stumbled in schizophrenia, it could find new life in Alzheimer’s disease

By PharmaVoice staff • June 5, 2026